Por­to­la gets EU clear­ance to mar­ket An­dexxa un­der new name; Four biotechs set terms for Nas­daq de­but

→ Por­to­la $PT­LA has made in­roads for its an­ti­co­ag­u­lant an­ti­dote in Eu­rope, win­ning a con­di­tion­al OK to mar­ket an­dex­anet al­fa as On­dexxya. Sold in the US as An­dexxa, the drug is de­signed to re­verse the blood thin­ning ef­fects of Fac­tor Xa in­hibitors like apix­a­ban and ri­varox­a­ban in acute sit­u­a­tions. Por­to­la’s fourth quar­ter rev­enue for 2018 was $15.3 mil­lion, $14 mil­lion of which was net prod­uct rev­enue from An­dexxa sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER